Literature DB >> 24126583

Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia?

Sun Young Cho1, Cheol-In Kang, Jungok Kim, Young Eun Ha, Doo Ryeon Chung, Nam Yong Lee, Kyong Ran Peck, Jae-Hoon Song.   

Abstract

A retrospective study was conducted to evaluate the efficacy of levofloxacin in the treatment of Stenotrophomonas maltophilia bacteremia. The 30-day mortality rates were similar between the trimerthoprim-sulfamethoxazole (TMP-SMX) and levofloxacin treatment groups. Adverse events related to antibiotics occurred more frequently in patients receiving TMP-SMX, and recurrent bacteremia due to levofloxacin-resistant S. maltophilia strains developed in patients treated with levofloxacin. Our data suggest that levofloxacin can be a useful alternative option for treating S. maltophilia infections.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24126583      PMCID： PMC3910801          DOI： 10.1128/AAC.01682-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia.

Authors:  K Weiss; C Restieri; E De Carolis; M Laverdière; H Guay
Journal:  J Antimicrob Chemother       Date:  2000-03       Impact factor: 5.790

2.  Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America.

Authors:  Leonard A Mermel; Michael Allon; Emilio Bouza; Donald E Craven; Patricia Flynn; Naomi P O'Grady; Issam I Raad; Bart J A Rijnders; Robert J Sherertz; David K Warren
Journal:  Clin Infect Dis       Date:  2009-07-01       Impact factor: 9.079

3.  Risk factors influencing mortality related to Stenotrophomonas maltophilia infection in hematology-oncology patients.

Authors:  Hayati Demiraslan; Mustafa Sevim; Çiğdem Pala; Süleyman Durmaz; Veli Berk; Leylagül Kaynar; Gökhan Metan
Journal:  Int J Hematol       Date:  2013-02-22       Impact factor: 2.490

4.  Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates.

Authors:  G Bonfiglio; C Cascone; C Azzarelli; V Cafiso; F Marchetti; S Stefani
Journal:  J Antimicrob Chemother       Date:  2000-01       Impact factor: 5.790

5.  Attributable mortality of Stenotrophomonas maltophilia bacteremia.

Authors:  Esin Senol; Jeffrey DesJardin; Paul C Stark; Laurie Barefoot; David R Snydman
Journal:  Clin Infect Dis       Date:  2002-05-24       Impact factor: 9.079

Review 6.  Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review.

Authors:  Matthew E Falagas; Politimi-Eleni Valkimadi; Yu-Tsung Huang; Dimitrios K Matthaiou; Po-Ren Hsueh
Journal:  J Antimicrob Chemother       Date:  2008-07-28       Impact factor: 5.790

7.  Stenotrophomonas maltophilia: an emerging opportunist human pathogen.

Authors:  W John Looney; Masashi Narita; Kathrin Mühlemann
Journal:  Lancet Infect Dis       Date:  2009-05       Impact factor: 25.071

8.  Levofloxacin and ciprofloxacin in vitro activities against 4,003 clinical bacterial isolates collected in 24 Italian laboratories.

Authors:  Giovanni Pietro Gesu; Federico Marchetti; Laura Piccoli; Annalisa Cavallero
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

9.  Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.

Authors:  Boubakar B Ba; Hala Feghali; Corinne Arpin; Marie-Claude Saux; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

10.  Antimicrobial susceptibility of stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates.

Authors:  Hae-Sun Chung; Seong Geun Hong; Young Ree Kim; Kyeong Seob Shin; Dong Hee Whang; Jee Young Ahn; Yeon-Joon Park; Young Uh; Chulhun L Chang; Jong Hee Shin; Hye Soo Lee; Kyungwon Lee; Yunsop Chong
Journal:  J Korean Med Sci       Date:  2013-01-08       Impact factor: 2.153
View more
  30 in total

1.  Clinical and Microbiologic Outcomes in Patients with Monomicrobial Stenotrophomonas maltophilia Infections.

Authors:  Cara Nys; Kartik Cherabuddi; Veena Venugopalan; Kenneth P Klinker
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

2.  Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole.

Authors:  M Biagi; X Tan; T Wu; M Jurkovic; A Vialichka; K Meyer; R E Mendes; E Wenzler
Journal:  J Clin Microbiol       Date:  2020-01-28       Impact factor: 5.948

3.  Novel Mechanisms of Efflux-Mediated Levofloxacin Resistance and Reduced Amikacin Susceptibility in Stenotrophomonas maltophilia.

Authors:  Punyawee Dulyayangkul; Karina Calvopiña; Kate J Heesom; Matthew B Avison
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

4.  Trimethoprim-Sulfamethoxazole Versus Levofloxacin for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 US Hospitals.

Authors:  Sadia H Sarzynski; Sarah Warner; Junfeng Sun; Roland Matsouaka; John P Dekker; Ahmed Babiker; Willy Li; Yi Ling Lai; Robert L Danner; Vance G Fowler; Sameer S Kadri
Journal:  Open Forum Infect Dis       Date:  2022-01-17       Impact factor: 3.835

5.  Characterization of the Bacteriophage BUCT603 and Therapeutic Potential Evaluation Against Drug-Resistant Stenotrophomonas maltophilia in a Mouse Model.

Authors:  Pengjun Han; Wenjing Zhang; Mingfang Pu; Yahao Li; Lihua Song; Xiaoping An; Mengzhe Li; Fei Li; Shuyan Zhang; Huahao Fan; Yigang Tong
Journal:  Front Microbiol       Date:  2022-07-05       Impact factor: 6.064

Review 6.  Clinical challenges treating Stenotrophomonas maltophilia infections: an update.

Authors:  Maria F Mojica; Romney Humphries; John J Lipuma; Amy J Mathers; Gauri G Rao; Samuel A Shelburne; Derrick E Fouts; David Van Duin; Robert A Bonomo
Journal:  JAC Antimicrob Resist       Date:  2022-05-05

7.  Whole-genome sequencing identifies emergence of a quinolone resistance mutation in a case of Stenotrophomonas maltophilia bacteremia.

Authors:  Theodore R Pak; Deena R Altman; Oliver Attie; Robert Sebra; Camille L Hamula; Martha Lewis; Gintaras Deikus; Leah C Newman; Gang Fang; Jonathan Hand; Gopi Patel; Fran Wallach; Eric E Schadt; Shirish Huprikar; Harm van Bakel; Andrew Kasarskis; Ali Bashir
Journal:  Antimicrob Agents Chemother       Date:  2015-08-31       Impact factor: 5.191

Review 8.  The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies.

Authors:  Thomas M Baker; Michael J Satlin
Journal:  Leuk Lymphoma       Date:  2016-06-24

9.  Risk Factors Associated with Stenotrophomonas maltophilia Bacteremia: A Matched Case-Control Study.

Authors:  Kosuke Sumida; Yong Chong; Noriko Miyake; Tomohiko Akahoshi; Mitsuhiro Yasuda; Nobuyuki Shimono; Shinji Shimoda; Yoshihiko Maehara; Koichi Akashi
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

Review 10.  Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options.

Authors:  Ya-Ting Chang; Chun-Yu Lin; Yen-Hsu Chen; Po-Ren Hsueh
Journal:  Front Microbiol       Date:  2015-09-02       Impact factor: 5.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.